BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

vascuVis Awarded NSF SBIR Phase I Funding to Establish Vascucap Feasibility in Marketplace for Detection of Vulnerable Atherosclerotic Plaques


12/7/2012 12:04:47 PM

Wenham, MA—vascuVis was awarded the highly competitive NSF SBIR Phase I funding for development of vascuCAP, to begin January 2013. The Wenham based company seeks to establish feasibility and market potential of vascuCAP, the company’s vascular disease computer-aided prognostic software.

The goal of Phase I research is a software development endpoint. CAP seeks to extend beyond static diagnostics to prognosticate the likely future progression of plaque vulnerability; previous approaches rely on identifying a small number of features hypothesized to be precursor to an acute event. The research objective is to develop an integrated segmentation, registration and classification MRI scan and computer aided analysis toolkit for prognosis prediction of stable or unstable plaque from longitudinal MRI data.

Distinguishing which vascular lesions will have favorable outcomes (versus unfavorable) requires quantification and feature characterization algorithms, in addition to sophisticated image analysis, accentuating the subtle imaging differences between these related pathologies.

We will demonstrate probable clinical utility by the successful extraction of values that meet or exceed the manually produced preliminary results from available animal and human MRI datasets.

This technology represents a cost effective, safe and capable plaque assessment tool, so that patients could be treated more effectively, sooner, and more appropriately. vascuCAP also creates an end-user capability that could be used in the 20,000 existing MRI units installed worldwide.

For more information contact Andrew Buckler, vascuVis President and CEO, (978) 468-0508, 225 Main Street, Suite 15, Wenham, MA 01984, Andrew.Buckler@vascuVis.com, www.vascuVis.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES